ClinicalTrials.gg
RecruitingNCT03341130TACOUpdated Sep 28, 2023

Determinants of Tooth Movement in Oral Appliance Treatment of OSA.

An interventional study of Mandibular Repositioning Splint and Mandibular Advancement Oral Appliance in Obstructive Sleep Apnea, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by University of British Columbia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2018; still recruiting 8 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Sleep Apnea, Obstructive by University of British Columbia — 4 open to participants now, 4 under way, none of them phase 3. Sleep Apnea, Obstructive · University of British Columbia.

Planned enrollment
Largest of 14
105 · median 31
Started
2018
with 3 others
No phase
12 of 16
3 open now
Registered
10th of 16
by date

Among the 16 studies in Sleep Apnea, Obstructive by University of British Columbia, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2018, is one of 12 with no phase, and was the 10th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

4 of the 16 studies in Sleep Apnea, Obstructive by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Apnea, Obstructive by University of British Columbia, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is a sleep related breathing disorder, affecting approximately 10% of adults. Mandibular advancement oral appliances (OAM) are an effective treatment for OSA, however, long term use has shown to lead to changes in teeth positioning and jaw alignment (bite changes), which has resulted in some patients stopping treatment.

It is becoming common clinical practice for doctors to prescribe the use of repositioning splints to help reduce the bite changes associated with using OAM. However, this has not been studied in a clinical trial.

This study will compare the bite changes between patients using OAM alone against patients using a morning repositioning splint in addition to OAM. Other variables, such as oral health, the size of mandibular advancement, and treatment adherence will also be measured to determine if they have an effect on the bite changes associated with OAM use.

By understanding the key the factors that influence the bite changes associated with OAM use and potentially validating a technique to reduce these changes, this study will improve the clinical practice of Dental Sleep Medicine, leading to improved health outcomes for OSA patients.

Read the detailed description

Mandibular advancement oral appliances (OAM) are an effective treatment for obstructive sleep apnea (OSA). However, prolonged OAM treatment leads to significant changes in occlusion for the majority of patients. As such it is not uncommon to find changes in occlusion and the resulting decrease in quality of life in long-term users of oral appliances to be cited as a reason for discontinuing OAM treatment. Understanding the determinants of occlusal changes and clinical strategies to minimize or prevent them are essential to the practice of Dental Sleep Medicine, where treatment success is predicated on high levels of adherence.

Morning Repositioners or alternative oral appliances/splints that counteract the muscle splinting of the mandible in a forward postured position have been advocated by some practitioners as a means of minimizing the occlusal changes associated with OAM treatment. However, this has not been studied in a prospective clinical trial.

The proposed study is a single-blinded prospective randomized controlled trial at three clinical centers, with the specific aim of assessing the effectiveness of mandibular repositioning splint use on minimizing the occlusal changes associated with OAM treatment. Secondary aims include also determining the effects of periodontal disease, treatment adherence, and magnitude of mandibular advancement on occlusal changes associated with OAM treatment.

90 OSA patients will receive OAM treatment following standard practices. A titration period of two months will be used to adjust the position of mandibular advancement for each patient, which will involve clinical follow-up visits at a minimum of 1 week, 1 month and 2 months after initiation of OAM treatment. Each participant will be randomly assigned to either the treatment or control group. The treatment group will receive a mandibular repositioning splint to wear for a minimum of 1 hour in the mornings following removal of OAM. A positive control group will receive no additional splint, and but will be managed using standard practices, including jaw stretching exercises as needed. A second negative control group consisting of 15 healthy adults not undergoing any oral appliance treatment will also be included.

Prior to receiving treatment, participants will undergo a baseline assessment where demographic, anthropometric, and specific periodontal health data will be collected. All measurements will be repeated at a minimum of 18 and 36 months after appliance insertion, with routine follow-up appointments and adherence data collected every six months.

To directly address the primary aim of this study, occlusal variables will be measured by a combination of methods including analysis of digitized dental models, cephalometric analysis and intra-oral radiography bone level measurements. Secondary outcome variables to assess the effectiveness of morning mandibular repositioning splint therapy will include average OAM adherence (hours/night), quality of life (Functional Outcomes of Sleep Questionnaire, FOSQ), and change in mandibular incisor root length and attachment loss. Adherence will be measured by compliance monitors embedded in the oral appliance and mandibular repositioning splints.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • OSA
  • Mandibular Advancement Splint
  • Oral Appliance
  • Treatment
  • Repositioning Splint
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment naive (have never used an oral appliance as treatment for OSA);
  • Age 25 - 65 years old, who are able to freely provide ;
  • (BMI) ≤ 35;
  • 8 or more teeth per arch to support treatment with OAM;
  • Apnea-Hypopnea Index (AHI) within the range 5≤AHI≤50 documented with polysomnography in the last 2 years ***OR***
  • Respiratory Disturbance Index (RDI) within the range 20 ≤ RDI ≤ 50 documented with level III portable sleep test ***OR***
  • Oxygen Desaturation Index (ODI) ≥ 10

Exclusion criteria

Exclusion Criteria:

  • Extensive periodontal disease with significant tooth mobility;
  • Inability to protrude jaw;
  • Insufficient vertical opening to accommodate treatment with OAM;
  • Pregnancy (if a participant becomes pregnant during the trial, the participant will be withdrawn from the study).
  • Uncontrolled congestive heart failure (defined as a prior clinical diagnosis, an ejection cut-off of 40% or clinical sign in the opinion of a primary care physician or cardiologist) that makes it unsafe in the opinion of the investigators for the subject to participate in the trial;
  • Coronary artery disease unless stable for at least 6 months and considered by the investigators to have a stable disease;
  • Any history of angina, myocardial infarction or stroke;
  • Any history of major depressive disorder along with current moderate-severe disease;
  • Active cancer management (unless in remission for more than 1 year);
  • Known renal failure (with need for dialysis)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.

    Device: Mandibular Repositioning Splint · Device: Mandibular Advancement Oral Appliance

  • Experimental
    Positive Control Group

    The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.

    Device: Mandibular Advancement Oral Appliance

  • No intervention
    Negative Control Group

    The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.

Interventions

  • DeviceMandibular Repositioning Splint

    The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.

    Also known as: Morning Repositioner, Morning Aligner

  • DeviceMandibular Advancement Oral Appliance

    Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.

    Also known as: OAM, MAS

06

What researchers measure

Primary outcomes

  1. Change in Overjet

    The change in the extent of horizontal (anterior-posterior) overlap of the maxillary central incisors over the mandibular central incisors, measured from digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

Secondary outcomes

  1. Treatment Adherence

    Adherence will be measured by the DentiTrac smart chip (Braebon Medical Corporation, Kanata, Canada) embedded in the oral appliance and mandibular repositioning splints. The adherence will be measured in hours per night and nights per week.

    Time frame: Data collected every 6 months after treatment commencement, up to 36 months.

  2. Quality of Life using Functional Outcomes of Sleep Questionnaire (FOSQ-10)

    FOSQ-10 measures functional status and difficulty in performing everyday activities via 10 questions. The range of scores for any question is from 1 to 4. There is also a 0 score option for participants who do not engage in a particular activity for other reasons, in which case the question will be excluded. There are 5 subscales that measure: general productivity, activity level, vigilance, social outcomes, and intimacy and sexual relationships. To obtain the total score, a mean-weighted item score is computed for those subscales with more than one item. To calculate a mean-weighted item score calculate the mean of the answered items with responses \> 1 for each subscale. The total score is then derived by calculating the mean of the subscale scores and multiplying that mean by five. Total score ranges between 5 and 20. Higher scores indicate better functional status.

    Time frame: Data collected at 0, 1, 2, 18 and 36 months after appliance insertion.

  3. Daytime Sleepiness

    Evaluation of OSA specific fatigue using Epworth Sleepiness Scale (ESS) questionnaire. ESS measures daytime sleepiness via 8 questions that ask about daytime sleepiness during common everyday conditions. The potential range of scores for any questions is from 0 to 3. Higher values represent worse outcomes. Their are no subscales for ESS. The answers to the questions are all summed up. Total score ranges between 0 and 24. A score above 10 indicates daytime sleepiness with higher scores indicating more sleepiness.

    Time frame: Data collected at 0, 1, 2, 18 and 36 months after appliance insertion.

  4. Change in Overbite

    Using digital dental model analysis to evaluate the change in the extent of vertical (superior-inferior) overlap of the maxillary central incisors over the mandibular central incisors, measured relative to the incisal edges.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

  5. Dental Crowding

    Changes in dental crowding, measured by digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

  6. Intermolar Distance

    Changes in distance between molars, measured by digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

  7. Intercanine Distance

    Changes in distance between canines, measured by digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

  8. Posterior Occlusal Changes

    Changes in the number of posterior teeth with open occlusal contacts, measured from digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

  9. Anterior Occlusal Changes

    Change in the number of anterior teeth in crossbite, measured from digital dental model analysis.

    Time frame: Data collected at 0, 18 and 36 months after appliance insertion.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Jul 2024, 71 months after the start.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 71 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 14, 2017
StartActual
Aug 22, 2018
Primary completionEst.
Jul 2024
CompletionEst.
Dec 2024
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03341130
Collaborators
Université de Montréal, Laval University
Responsible party
Benjamin Pliska (Assistant Professor, University of British Columbia) — Principal investigator
First posted
Nov 14, 2017
Start date
Aug 22, 2018
Primary completion
Jul 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Sep 28, 2023

Study contacts

Benjamin T Pliska, DDS
Contact
pliska@dentistry.ubc.ca
604-822-7237
Benjamin T Pliska, DDS
principal investigator · University British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion